Baird Rates Larimar Therapeutics (LRMR) buy, $5 Price Target

Baird analyst Joel Beatty reiterates a buy rating on LRMR with a price target of $5, a 56.25% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 8:01 AM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Baird rated Larimar Therapeutics, Inc. ($LRMR) "buy" with a $5 price target on June 30, 2026.

Since the rating, $LRMR is up 11.8% after 1 week, up 25.6% after 1 month and down 34.8% to date (from the $3.05 close on Jun 30, 2026).

LRMR Larimar Therapeutics, Inc.

$1.99 -42.65% year to date

Daily close · Oct 16, 2026

Key Points

Baird analyst Joel Beatty maintained a buy rating on LRMR, setting a price target of $5 on June 30, 2026.
Baird's $5 price target implies 56.25% upside from Larimar Therapeutics, Inc.'s ($LRMR) current $3.20 share price.
Shares of LRMR traded near $3.20 on Tuesday, with insider buying activity reported in May 2026.
Institutional investors like Deerfield Management and Millennium Management adjusted their LRMR holdings recently.

Get $LRMR trade alerts by text

We text you when insiders, Congress or big funds trade $LRMR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Larimar Therapeutics, Inc. alert may contain errors. Disclosures

Baird analyst Joel Beatty reiterated a buy rating on LRMR, setting a price target of $5 on June 30, 2026. This move comes as the stock traded near $3.20 on Tuesday.

Analyst rating track record

Baird vs. the S&P 500

YTD return +11.46% hypothetical

All-time return +17.08% S&P 500 +28.66%

vs. S&P 500 -11.58% behind the index

Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in LRMR

Several institutional investors have adjusted their positions in LRMR. Deerfield Management Company increased its holdings by 5 million shares, ending with 35,606,974 shares valued at about $160.2 million, a 16.3% increase. Blue Owl Capital Holdings LP added 296,317 shares, bringing its total to 7,120,007 shares worth approximately $32 million, a 4.3% rise. BlackRock, Inc. also grew its position by 70,597 shares to 3,752,200 shares, valued at around $16.9 million, marking a 1.9% increase. Conversely, Millennium Management LLC reduced its stake by 1,581,086 shares to 3,625,278 shares, a decrease of 30.4%.

Insider Buying and Selling at Larimar Therapeutics, Inc.

On May 19, 2026, several insiders, including Joseph Truitt, Jonathan Leff, Jeffrey Sherman, Frank Thomas, Thomas Edward Hamilton, and James Flynn, each purchased 55,150 shares of LRMR. These transactions were not part of a pre-planned Rule 10b5-1 trading plan.

Analysts Set New Price Targets

On June 30, 2026, Baird maintained its buy rating on LRMR with a price target of $5. Earlier, on May 27, 2026, JP Morgan initiated a buy rating with a $9 target. Wedbush has consistently maintained a buy rating, with targets ranging from $11 to $13 over recent months. Citigroup also maintained a buy rating with a $14 target in February 2026.

Bottom Line

Baird's reaffirmation of a buy rating with a $5 price target for LRMR highlights continued analyst confidence. Shares have seen institutional adjustments, with significant insider buying activity in May 2026. Investors should note that these analyst ratings and institutional activities provide insights into market sentiment but are backward-looking and not indicative of future performance.

12-month forecast